Latest News for 03/2020
30 Jan 2020
Sumitomo Dainippon Pharma and Exscientia announce that a phase I clinical study of DSP-1181, that was created using Artificial Intelligence (AI), has been initiated in Japan for the treatment of obsessive-compulsive disorder as an initial indication.
21 Mar 2019
Exscientia, a world leader in artificial intelligence (“AI”) driven drug discovery and a spinout company of the University of Dundee announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program.
07 Jan 2019
Exscientia, a world leader in artificial intelligence (“AI”) driven drug discovery and a spinout company of the University of Dundee, has made two announcements today regarding major investments and collaboration.
28 Sep 2017
* EVOTEC INVESTS in Exscientia to advance AI-driven DRUG DISCOVERY Evotec AG and Exscientia Ltd - a company ‘spun out’ from research at the University of Dundee - today announced that Evotec has made a € 15 m investment to take a minority stake in Exscientia.
05 Jul 2017
Pre-clinical collaboration focused on up to 10 targets nominated by GSK
20 Jun 2017
Dundee University spin-out company, Exscientia, won two awards at the Chemistry Means Business 2017 Awards, hosted by the UK Royal Society of Chemistry in Manchester last week. Its Chief Executive Officer Andrew Hopkins has been named Chemistry World ‘Entrepreneur of the Year’ and Chief Technology Officer Jérémy Besnard won the ‘Rising Star in Industry’ Award for their work at Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery.
19 May 2017
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease. Exscientia is a spin-out company from the School.
16 Nov 2016
The University of Dundee announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. The project will enable a unique collaboration bringing together expertise at Dundee in male fertility and drug discovery to help identify possible new male contraceptive drugs.
07 Mar 2016
The Royal Society of Edinburgh has announced today that four people from the University of Dundee have been elected as Fellows of the RSE, three of whom are from the Schools of Life Sciences. The new Fellows from the University are: · Wendy Alexander, Vice-Principal (International) · Paul Birch, Professor of Plant Pathology and Deputy Head of the Division of Plant Sciences
20 Jan 2016
The Universities of Dundee, Oxford and Edinburgh have announced the formation of the Phenotypic Discovery Initiative (PDi) with Janssen Pharmaceutica N.V. the first industry partner joining the initiative. A phenotype is one or more observable features or traits that report changes in a biological system or its reaction its environment. Phenotypic screening is the systematic identification of agents (such as small molecules, biological molecules or genetic mutations) that alter a phenotype.